Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

A team of scientists from China has successfully created a miniature womb on a chip that mimics the complex environment of ...

Abstract: This paper analyzes a DC-DC isolated bidirectional resonant converter topology, designed to achieve high voltage gain with minimal power loss, enabling modular integration between ...

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results. Krish Patel, MD, director of the Lymphoma Research ...

Did you know that chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults? Estimates project over 23,600 diagnoses and nearly 4,500 deaths from this slow-growing blood cancer ...

Researchers recently developed a bone marrow model to study how the body generates cells. Interestingly, this model is the first of its kind to be developed entirely from human cells. Not only can ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Without even thinking about it, the bone marrow in your body is ...

Our body’s “blood factory” consists of specialized tissue made up of bone cells, blood vessels, nerves and other cell types. Now, researchers have succeeded for the first time in recreating this ...

Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...

Japanese battery maker and Tesla supplier Panasonic is working on a breakthrough electric vehicle battery chemistry. The company is working on anode-free lithium metal batteries, which can boost ...

CLL cells exploit the TME, particularly BMSCs, to enhance survival and therapy resistance through AP-1 activation. Core regions in 3D cultures show greater CLL B cell survival and resistance compared ...